Melinta Therapeutics terminated the $57m acquisition of Tetraphase Pharmaceuticals.

Melinta Therapeutics, an American biopharmaceutical firm, terminated the $57m acquisition of Tetraphase Pharmaceuticals, a biopharmaceutical company. “This transaction increases our world-class infectious disease portfolio and we are eager to build upon our synergies and leverage our collective expertise and scale to offer patients and providers battling serious bacterial infections with an additional potentially life-saving treatment option,” Jennifer Sanfilippo, Melinta Interim CEO.